Immune Effector Cell (IEC) Therapies

All times below listed in ET

Co-chairs: Catherine Bollard, MD, and Stephen Gottschalk, MD

Register for Immune Effector Cell (IEC) Therapies 

1:00 – 1:20 p.m.

Lymphoma Post PiggyBac-Modifed CD19 CAR T-Cell Therapy
David Bishop, BMedSc(Hons), MBBS, PhD, FRACP, FRCPA. The University of Sydney, Westmead Hospital

1:20 – 1:40 p.m.

PSMA-Directed/TGFβ-Insensitive CAR T-Cell Therapy
Naomi Haas, Abramson Cancer Center, University of Pennsylvania

1:40 – 2:00 p.m.

CarHLH - An Initially Overlooked Complication of CAR T-Cell Therapy
Nirali N. Shah, MD, MHSc. National Cancer Institute, National Institutes of Health

2:10 – 2:30 p.m.

Peptide-Centric CAR-T Cells to Target Intracellular Antigens
John Maris, MD, Children's Hospital of Philadelphia

2:30 – 2:50 p.m.

TruCs: An Alternative Synthetic T Cell Receptor
Robert Hofmeister, PhD, TCR2 Therapeutics, MA

2:50 – 3:10 p.m.

Gene Editing to Improve CAR T-Cell Therapy
Giedre Krenciute, PhD, St. Jude Children's Research Hospital

3:40 – 4:00 p.m.

Modulating CAR Signaling to Prevent or Reverse Exhaustion
Evan Weber, PhD, Stanford University School of Medicine

4:00 – 4:20 p.m.

Transcriptional Engineering of CD8 TILs
Patrick G. Hogan, PhD, La Jolla Institute for Immunology

4:20 – 4:40 p.m.

Engineering CAR-T Cells With Improved Effector Function
Barbara Savoldo, MD, PhD, University of North Carolina at Chapel Hill